| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 18892239720 |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Mal-amido-PEG3-C1-NHS ester CAS:2101206-45-3 Package:100mg;250mg;500mg
|
| Company Name: |
Shanghai Yanfen Biochemical Technology Co.,LTD
|
| Tel: |
17721070236 15002190549; |
| Email: |
yanfen2023@126.com |
| Products Intro: |
Product Name:2,5-dioxopyrrolidin-1-yl 2-[2-(2-{2-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido]ethoxy}ethoxy)ethoxy]acetate CAS:2101206-45-3 Purity:>=95% Package:1g;5g;25g;100g;
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Email: |
sales@medchemexpress.com |
| Products Intro: |
Product Name:Mal-amido-PEG3-C1-NHS ester CAS:2101206-45-3
|
|
| | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester Basic information |
| Product Name: | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester | | Synonyms: | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester;Mal-amido-PEG3-C1-?NHS ester;2,5-dioxopyrrolidin-1-yl 2-[2-(2-{2-[3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido]ethoxy}ethoxy)ethoxy]acetate | | CAS: | 2101206-45-3 | | MF: | C19H25N3O10 | | MW: | 455.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2101206-45-3.mol |  |
| | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | pka | 15.00±0.46(Predicted) |
| | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester Usage And Synthesis |
| Uses | Mal-amido-PEG3-C1- NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). | | IC 50 | Non-cleavable Linker | | References | [1] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. DOI:10.1038/nrd.2016.268 |
| | 3,6,9-Trioxa-12-azapentadecanoic acid, 15-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-13-oxo-, 2,5-dioxo-1-pyrrolidinyl ester Preparation Products And Raw materials |
|